Kailian Medical Completes C+ Round of Over $10 Million, Less Than a Month After Its Series C Funding

VCBeat (WeChat ID: vcbeat) has learned that Kailian Medical Technology (Shanghai) Co., Ltd. (“Kailian Medical”) recently completed a new round of C+ financing. Existing investors Qianhai Equity Investment Fund and Legend Capital increased their stakes, with the investment amount exceeding tens of millions of US dollars. This comes less than one month after Kailian Medical closed its previous C-round financing of over 100 million yuan. To date, Kailian Medical has completed four rounds of financing.

Kailian Medical has obtained NMPA registration certifications for products including the Kailian Lepump® Insulin Pump, Kailian Yinuo® Pituitary Hormone Injection Pump, disposable pump reservoirs, and infusion sets, and has successfully launched these products onto the market.

Several domestic experts in the field of endocrinology, when evaluating Kailian Medical, pointed out, “We look forward to seeing domestically produced infusion devices for endocrine diseases embark on a path of innovative, independent research and development, while simultaneously enhancing quality, improving craftsmanship, and reducing costs. This will provide clinical settings with products that are affordable and effective for the general public, enabling patients with endocrine disorders to lead normal lives.”

Kailian Medical is firmly committed to the path of independent R&D and intelligent manufacturing in China, strengthening product development investment by combining its R&D capabilities with insights into clinical needs.

In the field of diabetes care, Kailian Medical leverages its independently developed micro-infusion and control technologies as its core competency. The company is currently advancing the iterative R&D, clinical validation, and regulatory approval processes for its drug infusion hardware products. While accelerating the commercialization of its existing portfolio, Kailian Medical is progressively launching new offerings—including the LePump® Insulin Pump Generation II, electric insulin pens, and patch insulin pumps—to comprehensively strengthen its product layout for insulin delivery in diabetes management.

Meanwhile, in view of the diversity and broad prospects of micro-dose infusion applications in endocrinology, Kailian Medical is actively collaborating with multiple partners to explore wider clinical applications of the Kailian Yinuo® pump and to develop corresponding products based on microneedle transdermal drug delivery technology, which will be applied in various fields such as medical aesthetics and medical transdermal drug delivery in the future.

Kailian Medical not only develops and manufactures hardware products for micro-dose drug infusion, but also builds the Kailian Cloud Management Platform by integrating communication and internet medical technologies, thereby expanding more possibilities for chronic disease management models.

Leveraging years of service management experience in the field of chronic diseases, Kailian Medical will launch a lifestyle intervention management tool to help patients with polycystic ovary syndrome (PCOS), diabetes, and other conditions manage multiple dimensions including nutrition, diet, exercise, and monitoring. The company’s initial focus is on preventive chronic disease management, embodying the principle of “prevention before occurrence.” Built upon hardware products, the Kailian Cloud Management Platform pioneers an integrated smart management system for both in-hospital and out-of-hospital chronic care, establishing a collaborative care network involving physicians, patients, and their families and friends. Furthermore, the Kailian Cloud Management Platform features strong technical openness, enabling cooperation with more enterprises to comprehensively manage prevention, monitoring, and treatment data, thereby laying the foundation for developing a closed-loop system that meets the needs of patients with chronic diseases.

Kailian Medical extends its gratitude to both new and existing investors for their recognition and support. As a domestic enterprise specializing in medical devices for micro-dose drug infusion, Kailian Medical has refined its product pipeline and application layout in alignment with its corporate development strategy. While advancing the commercialization of its marketed products, the company will further launch several blockbuster micro-dosing therapeutic products and disease management systems to address current unmet clinical needs.

Duan Xufang, Executive Director of Qianhai Ark Asset Management Co., Ltd., stated, “Kailian Medical possesses a first-class proprietary micro-infusion drug delivery platform technology and industrialization capabilities. By continuously launching innovative products, it provides patients with diabetes, infertility, developmental delays, and other conditions with intelligent drug delivery devices and management systems that offer superior quality, better cost-effectiveness, and greater ease of use. Through concrete actions, the company has fully embodied its corporate philosophy—‘We cannot change diseases, but we can improve patients’ lives’—safeguarding the healthy living of patients with chronic diseases. As an existing shareholder, Qianhai Fund of Funds fully recognizes Kailian Medical’s technological leadership and platform potential, and is committed to continuing its support for the company’s development, working together to build a domestic leading micro-infusion drug delivery platform.”

Wang Junfeng, Co-Chief Investment Officer at Legend Capital, stated, “Legend Capital has consistently focused on addressing unmet clinical needs within the spectrum of major diseases. As diabetes has become one of the significant threats to human health, we have maintained a strong focus on investments in the diabetes sector. We hope that the Kailian team will emerge as a pioneer in diabetes prevention and treatment, thereby improving the quality of life for individuals with diabetes.”

“As one of Kailian Medical’s earliest investors, we deeply admire Mr. Huang Xiaomin’s extensive industry experience and unwavering professional dedication. Under his leadership, the team has demonstrated remarkable perseverance over the years, particularly showcasing strong execution and cohesion during the pandemic. Kailian Medical has now achieved key milestones and successfully completed a new round of financing. We look forward to continuing our partnership with the Kailian team to contribute to the advancement of human health.”